NCT04842617Active, not recruitingPhase 3
A Multicenter, Randomized, Double-blind Phase III Study：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.1 site in 1 country5,274 target enrollmentStarted: April 30, 2021Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 3
- Status
- Active, not recruiting
- Enrollment
- 5,274
- Locations
- 1
- Primary Endpoint
- IDFS（Invasive Disease-Free Survival）
Study Overview
Brief Summary
The study is to evaluate the efficacy and safety of SHR6390 combined with endocrine therapy for the adjuvant treatment of hormone receptor positive,Human Epidermal Receptor 2 negative.
To observe the PK characteristics of SHR6390 combined with endocrine therapy for the adjuvant treatment of hormone receptor positive,Human Epidermal Receptor 2 negative.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Postmenopausal or premenopausal/perimenopausal female patients aged ≥18 years and ≤75 years old.
- •Pathological examination diagnosed as invasive breast cancer with HR+ and HER2-.
- •Underwent radical resection of breast cancer.
- •The score of ECOG was 0 -
- •Fertile women must have a negative serum pregnancy test within 7 days before randomization, and be willing to use acceptable non hormonal contraceptive measures.
- •With my consent and informed consent, I am willing and able to comply with the planned visit, study treatment plan, laboratory examination and other test procedures.
Exclusion Criteria
- •This Pathological examination diagnosed as HER2-positive breast cancer.
- •The history of any malignant tumor other than breast cancer within 5 years before randomization.
- •At the same time participate in other anti-tumor therapy clinical trials (including endocrine therapy or immunotherapy, etc.).
- •In the 6 months before randomization, the following conditions occurred: myocardial infarction, severe/unstable angina pectoris, , etc
- •Inability to swallow, intestinal obstruction, or other factors that affect the administration and absorption of the drug.
- •There are other serious physical or mental illnesses or laboratory abnormalities that may increase the risk of participating in the study, or interfere with the results of the study, as well as patients who the investigator believes are not suitable for participating in this study.
Arms & Interventions
Treatment group B
Placebo Comparator
Intervention: placebo (Drug)
Treatment group A
Experimental
Intervention: SHR6390 (Drug)
Outcomes
Primary Outcomes
IDFS（Invasive Disease-Free Survival）
Time Frame: at least 5 years from the date of randomization .
Secondary Outcomes
- DDFS(Distant Disease-Free Survival)(from randomization to distant recurrence or death from any cause, whichever occurs first. Evaluations were conducted every 26 weeks for the first 2 years and every 52 weeks thereafter, with a follow-up of at least 5 years.)
- DFS(Disease-Free Survival)(The observation time is at least 5 years from the date of randomization . Evaluations were conducted every 26 weeks for the first 2 years and every 52 weeks thereafter, with a follow-up of at least 5 years.)
- Number of Participants With adverse events (AEs) and serious adverse events (SAEs) Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v5.0.(up to approximately 5 years)
- OS(Overall Survival)(up to approximately 5 years.)
- Plasma concentration of SHR6390 will be analyzed for PK samples(collected on day 1 of the 5th, 9th, 13th and 17th weeks, respectively.)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Unknown
Phase 3
A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast CancerAdvanced Breast CancerNCT03927456Jiangsu HengRui Medicine Co., Ltd.357
Unknown
Phase 3
A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast CancerAdvanced Breast CancerNCT03966898Jiangsu HengRui Medicine Co., Ltd.426
Recruiting
Phase 2
Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast CancerLocally Advanced or Metastatic Breast CancerNCT05860465Shanghai Pharmaceuticals Holding Co., Ltd254
Completed
Phase 1
A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast CancerAdvanced Breast CancerNCT03481998Jiangsu HengRui Medicine Co., Ltd.104
Recruiting
Phase 2
Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.Breast Cancer Brain MetastasesNCT05872347Shanghai Pharmaceuticals Holding Co., Ltd52